Replies to post #11 on Oxford BioMedica PLC (OXBDF)

[marcusl2]

You are correct George. I should have said if the treatment is expanded beyond Leukaemia.

The early-stage trial of CTL019 engineered cells conducted by researchers at the University of Pennsylvania indicates the potential of the complicated treatment, which analysts have estimated may generate $10 billion a year if its uses expand beyond leukemia. The therapy can provoke serious side affects, however, and eight of the 30 patients required intensive care for severe cytokine-release syndrome.

“We are excited by these results, which indicated how effective CTL019 may be in fighting ALL, a leading cause of childhood cancer deaths,” said lead investigator Stephan Grupp, a professor at the university.